| Assessment Status | Rapid Review Complete |
| HTA ID | 26055 |
| Drug | Upadacitinib |
| Brand | Rinvoq® |
| Indication | Upadacitinib (Rinvoq®) for the treatment of non-segmental vitiligo in adults and adolescents 12 years and older who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 07/10/2026 |
| Rapid review completed | 02/11/2026 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost-effectiveness of upadacitinib (Rinvoq®) compared with the current standard of care. |